• Job Description

  Req#: 73156
  Overview The Director/Head of Competitive Intelligence (CI) at Alnylam Pharmaceuticals plays a pivotal role in guiding the organization's strategic decisions by delivering actionable intelligence and insights on the competitive landscape. This role involves close collaboration with Commercial, Medical Affairs, Development, Research, Investor Relations, and Corporate Strategy/BD. The role will be expected to provide a holistic view of the competitive environment across all regions and for the entire portfolio and demands a forward-thinking leader ready to shape the next era of the CI function and provide impeccable service to all business units. This position is hybrid and will be primarily located in our Cambridge, MA office. Key Responsibilities · Strategic Leadership: Provide a vision and roadmap for the evolution of the CI function, ensuring it remains ahead of industry benchmarks and best practices. · Stakeholder Engagement: Collaborate closely with senior and executive leadership across all functions to deliver critical competitive insights and alignment with business objectives. · Intelligence Gathering and Synthesis: Oversee the collection, analysis, and dissemination of competitive information, drawing from diverse sources to provide a 360-degree view of the competitive landscape. · Portfolio Support: Deliver insights for the entire product portfolio, from approved drugs to early-stage research programs, ensuring every unit remains competitively positioned. · Cross-functional Collaboration: Establish strong working relationships with departments across the company, ensuring that CI insights are integrated into their strategic and operational plans. · Global Coverage: Monitor and analyze competitive movements and trends across all countries, adapting CI strategies to regional nuances. · Team Leadership: Mentor, guide, and develop a high-performing CI team, fostering a culture of collaboration, innovation, and continuous learning. Be a collaborative member of the Global Insights and Analytics Leadership Team · Customer Service: Ensure all CI activities are conducted with a customer-centric mindset, delivering actionable and timely insights to internal stakeholders. · Travel & Engagement: Represent the company at international forums, conferences, and meetings to gather firsthand intelligence and network with industry peers. · Network: Build diverse internal and external networks for primary intelligence gathering and cross-validation. Oversee development of presentations with clear storylines to communicate key conclusions and recommendations to Senior Leadership. · Scenario planning Lead all competitor and scenario planning exercises during pre-launch (e.g., War Games, etc.) and post launch (e.g., annual brand level situation analysis, etc.) Qualifications · Education: A Bachelor's degree in Business, Science, or a related field. An advanced degree (MBA, PhD, or equivalent) is preferred. · Experience: Minimum of 8 years of experience in Competitive Intelligence, Business Strategy, or Market Research in the pharmaceutical industry. · Proven track record of operating in a global environment and understanding diverse markets. · Leadership: Demonstrated ability to lead cross-functional teams, influence senior leadership, and drive strategic initiatives. · Exceptional analytical and problem-solving skills with a keen ability to distill complex information into actionable insights. · Excellent written and verbal communication skills, with the ability to present complex information clearly and persuasively. · Strong customer service orientation with a proven record of supporting internal stakeholders. · A desire to innovate and elevate the CI function, staying abreast of industry trends and technological advancements. · Travel: Willingness and ability to travel internationally as required by the role. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Alnylam is an E-Verify employer.

• About the company

  Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases.

Notice